A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain

CONCLUSIONS: Avacopan is a cost-effective option for patients with severe, active AAV compared to GC in Spain.PMID:38126738 | DOI:10.1080/14737167.2023.2297790

Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 21, 2023 Category: Health Management Authors: Manuel Mac ía Montserrat D íaz-Encarnación Roser Solans-Laqu é Elisenda Pomares Mallol Alejandra Garc ía Castells Cristina Escribano Antonio Ram írez de Arellano Source Type: research